Skip to main content
JBIO logo

JBIO · Jade Biosciences, Inc.

Track JBIO — free
$15.31 +0.25 (+1.66%) At close · Nov 20
Market Cap
$1.06B
Shares
69.19M
Volume · Nov 20 1.02M Avg daily vol (3M) 911.9K

Price & Indicators

 

Key stats

Close
$15.31
Fri 20 Nov
Open
$15.00
Fri 20 Nov
Average volume, 30 days
921K
shares a session
Short interest
10.4M
15.0% of shares · 14.1 days to cover
Day range
$15.00$15.54
Open $15.00 Close $15.31
52-week closing range
$11.48$26.85
Close $15.31 43.0% under the high
Short volume, last session
81%
Last earnings
Mar 10, 2026
Latest filing
10-Q · Nov 13
Price history
Jun 2021 to Nov 2026

Latest documents

2026
Nov 17
Investor event
Phase 3 trial starts this quarter, before Phase 2 data arrives

Jade Biosciences plans to start the Phase 3 trial of Jade 101 in IgA nephropathy this quarter, before Phase 2 data arrives in the second quarter of next year. It says Phase 2 data won't inform Phase 3 design.

5 source passages
Our lead program is Jade 101. We've actually recently updated our guidance to say we'll initiate the Phase 3 trial in IGA nephropathy this quarter We've guided that we're going to provide data in the second quarter of next year, but we're not waiting for that data to initiate a Phase 3. so we're moving rapidly towards a Phase 2 readout. we don't think the phase two is informative for phase three design. Open the document at this passage
Nov 16
Investor event
Jade 101 phase three trial start nears

Jade Biosciences aims to initiate a phase three trial this quarter, read out Jade 101 Phase 2 data in Q2-2027, and plans three readouts in 2027.

3 source passages
You could give us an introduction to Jade Biosciences. We're currently in a Phase 2 trial, moving very quickly towards a data readout in Q2-2027, so a big, meaningful event for us with 101 next year. But also, we're not waiting for that data. We have so much conviction in this mechanism and the data from our phase one trial that we're aiming to initiate a phase three trial actually this quarter. Yeah, we've got a big year next year with three readouts across all our programs. Open the document at this passage
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
JADE101 Phase 3 trial planned for fourth quarter of 2026

Jade Biosciences plans to initiate the JADE101 EVERGREEN Phase 3 trial in the fourth quarter of 2026. Net loss was $35.1 million for three months and $131.2 million for nine months ended September 30, 2026, while cash and investments totaled $475.7 million.

Net loss $35.06M Diluted EPS -$0.42
Read from the MD&A section
5 source passages
EVERGREEN is our planned Phase 3, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of JADE101 in patients with biopsy-confirmed primary IgAN receiving stable standard-of-care therapy. We plan to initiate EVERGREEN in the fourth quarter of 2026. As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” “the Company,” or “Jade,” refer to Jade Biosciences, Inc. and its consolidated subsidiaries, taken as a whole. We have generated net losses of $35.1 million and $131.2 million for the three and nine months ended September 30, 2026, respectively. As of September 30, 2026, we had cash and cash equivalents, and investments of $475.7 million. Open the document at this passage
Nov 13
Current report 8-K
EVERGREEN Phase 3 set for fourth quarter 2026

Jade Biosciences reported $475.7 million in cash, cash equivalents and investments as of September 30, 2026, expected to fund operations into the fourth quarter of 2028. The EVERGREEN Phase 3 trial is expected to begin in the fourth quarter of 2026.

Financial results
3 source passages
Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the third quarter ending September 30, 2026, and provided a corporate update. As of September 30, 2026, Jade had cash, cash equivalents, and investments of $475.7 million. Based on its current operating plans, Jade believes that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2028. Jade expects to initiate EVERGREEN, a Phase 3 registrational trial of JADE101 in IgAN, in the fourth quarter of 2026, reflecting the Company’s rapid execution as JADE101 advances into registrational development. Open the document at this passage
Nov 11
Investor event
Jade 101 Phase III expected to start this quarter

Jade Biosciences plans to begin a Phase III for Jade 101 in IGA nephropathy this quarter, with Phase II interim results in the second quarter of 2027; Phase I showed around 70 percent reduction in IgA at the 700 milligram dose.

5 source passages
So Jade Biosciences, we are a company that was founded in 2024 with monoclonal antibodies focused on autoimmune diseases. Our lead program is Jade 101, which is an anti-April monoclonal antibody being initially developed for the treatment of IGA nephropathy with the potential to expand indications. Our phase three is expected to initiate this quarter as well, so we're moving at a very rapid clip. We'll have the Phase II interim results in the second quarter of 2027. We saw at the 700 milligram dose level a reduction in IgA around 70 percent, which is higher than had been seen by our competitors previous to that Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$163.12M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
1.8
Trailing earnings · reciprocal yield 55.5%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$475.71M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+81.3%
Year over year · more shares
Price change (1Y)
+33.4%
Trailing year
Short interest
15.0%
Latest settlement · 14.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg +2%
above
RSI (14) 51
neutral
MACD trend Positive
52-week position 25%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +5%
trailing
6-month return −14%
trailing
YTD return −1%
this year
Relative strength −5%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $15 › 200d $18 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
14.99% of shares out · ▼ -7.5% MoM · 14.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
163 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Fair
EPS growth +96%
Y/Y
Free cash flow $-94.9M
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −50%
past year
ATR 6.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
+2% Bullish
RSI (14)
51 Neutral
MACD trend
Positive Bullish
52-week position
25% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $15 › 200d $18 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
14.99% of shares out · ▼ -7.5% MoM · 14.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
163 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11 Now $15 · 25% Range high $27
vs 200-day avg -16% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
JBIO
Jade Biosciences, Inc.
this stock
$1.06B -0.8% — — 15.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
163
% held
118.3%
Net QoQ
+8.9M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
146
View
Short & Settlement
Short Interest Falling
Shares short
10.4M
Days to cover
14.1d
Change
-836.0K sh
View
Short Volume
Short vol %
81%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
195
Value
$2.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
50.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-127.4M
EPS diluted
$-3.19
View
Buybacks
Remaining
shares 1.1M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
31

Jade Biosciences plans to start the Phase 3 trial of Jade 101 in IgA nephropathy this quarter, before Phase 2 data arrives in the second quarter of next year. It says Phase 2 data won't inform Phase 3 design.

View
Proposed Sales
Value
$303.7K
Shares
29.0K
Filed
Jun 25, 2025
View
Exempt Offerings
Offering
$75.8M
Filed
Aug 14, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Jade Biosciences Reports Third Qu…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
JBIO -5.1% +4.9% -13.8% +8.9% -0.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +3.4% +14.2% -4.6% +17.6% -1.9%

Capital returns

Latest dividend
$2.40 / share · ex Apr 29, 2025
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
—
Spent (derived)
—
Remaining
shares 1.13M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1798749 CUSIP 008064206 13F (30d) 160 filings 151 filers Visit website Investor relations